Education sets the basis for an AI-driven future of oncology
The deployment of artificial intelligence could lead to substantial advances in cancer care, but collaborative efforts are needed to increase trust among end users
Does artificial intelligence have a place in precision oncology?
Applications in artificial intelligence have the potential to transform precision oncology, but data quality and clinical validation of tools are still challenging
Cancer Research
Use of ctDNA as a surrogate in early clinical drug development – nearing its end point?
Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed
Studies confirm the promise of ctDNA for MRD assessment in colorectal cancer, but limitations remain
Despite positive results from trials, the use of different assays with variable sensitivities and specificities impact their interpretation and clinical validation
Performance data from AI tools show progress in oncology
Cancer imaging and identification of predictive biomarkers are the best performed tasks reported in studies presented at ESMO Congress 2023
New PAGAs on endometrial cancer and metastatic breast cancer presented in Singapore
Differences in cancer population, local expertise, availability of and accessibility to treatments are incorporated into two new Pan-Asian adaptations (PAGA) of the ESMO Clinical Practice Guidelines
How to improve cervical cancer screening in low- or middle-income countries?
Data presented at the ESMO Gynaecological Cancers Congress 2022 confirm the vital role of national screening programmes and highlight the importance of local access
Assessing pathological response after neoadjuvant treatment for NSCLC
Much progress has been made in the standardisation of pathological response but optimising viable tumour cutoffs for predicting long-term outcome after different treatment modalities and by histological type remain key areas for investigation
Pathogenic germline variants are more common than ‘incidental’
Tumour-only molecular profiling can spot hereditary cancer syndromes but resources are critical to make the most of this piece of information
How can exosome research improve patient management?
As the literature on exosomes continues to grow in cancer basic science, important questions remain regarding opportunities in the clinic